37 The Drug Rediscovery Protocol maximum tumour shrinkage compared to baseline sizes. Percentages were calculated with 95% confidence intervals using the Clopper–Pearson method. Kaplan–Meier methods were used to estimate overall survival (calculated from the first day of treatment administration to the date of death from any cause, censoring patients who were alive at the final follow-up), PFS (from the start of treatment to progression or death from any cause, whichever came first, and censoring patients who were alive without progression at final follow-up and time on treatment (censoring patients who had not finished treatment at the time of analysis). ACKNOWLEDGEMENTS We thank the Barcode for Life Foundation and the Dutch Cancer Society for their financial support; Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Merck Sharp and Dohme, Novartis, Pfizer and Roche for their in-kind and financial support; the HMF for their in-kind support by performing sequencing and biomarker analyses on baseline biopsies; the Center for Personalized Cancer Treatment Multidisciplinary Expert Board for supporting the central case-review process; the Independent Data Monitoring Committee for their advice on cohort decisions and the monitoring of preliminary safety data; the Netherlands Cancer Institute’s Biobank Facility, Scientific Department and Pharmacy for their facilitating services; A. P. Hamberg, L. V. Beerepoot and J. M. Meerum-Terwogt for their contributions to trial recruitment; and all participating hospitals for supporting and facilitating the conduct of the DRUP trial. 2
RkJQdWJsaXNoZXIy MTk4NDMw